Utilizing Risk Scores in Determining the Optimal Revascularization Strategy for Complex Coronary Artery Disease

Abstract

Percutaneous coronary intervention (PCI) of multivessel and/or left main stem disease have been shown to be potentially legitimate revascularization alternatives in appropriately selected patients. Risk stratification is an important component in guiding patients to identify the most appropriate revascularization modality (PCI or coronary artery bypass grafting [CABG]) in conjunction with the Heart Team. The aim of this paper is to give the clinician a concise overview of the important established and evolving contemporary risk models in aiding this decision-making process. Risk models, based on clinical and anatomical variables alone, the novel concept of functional anatomical risk scores, and risk models combining aspects from both clinical and anatomical scores, are all discussed. The emerging concepts of the patient-empowered risk/benefit tradeoff between PCI and CABG to help personalize the choice of revascularization modality are also explored.

Introduction

Risk stratification is an integral and increasingly important aspect of the assessment of patients with complex coronary artery disease who are candidates for coronary revascularization. Although the landmark SYNTAX trial established that surgery was the standard of care for patients with left main stem (LMS) and/or multivessel disease, an important finding from this study was that patients with less complex disease were found to have equivalent outcomes to surgery at 1 and 3 years' follow-up [1, 2•, 3].

The “Heart Team” approach in managing these complex patients was pioneered within the SYNTAX trial, and has recently been incorporated as a class I recommendation in recent myocardial revascularization guidelines [4]. As part of this approach, risk models to appropriately stratify patients are crucial to aid in the decision-making process regarding the choice of revascularization modality. Within cardiothoracic practice, the use of risk scores are well established and are predominantly related to clinical variables alone, with the EuroSCORE (European System for Cardiac Operative Risk Evaluation) being in widespread contemporary use [5, 6].

With percutaneous coronary intervention (PCI) of complex coronary artery disease, the risk models are still evolving, with models consisting of clinical or anatomical variables alone or combinations of the two variable types. Whereas anatomical variables have been shown to be less important for surgical outcomes, the SYNTAX trial and subsequent studies have confirmed these to be of significant importance for multivessel PCI [7, 8]. However, there is recognition that both anatomical and clinical variables are required to appropriately risk stratify patients contemplating percutaneous revascularization.

The purpose of this review article is to explore the numerous types of risk scores that are available that take into account either anatomical or clinical variables alone or a combination (Table 1). We also aim to highlight areas of potential further developments of contemporary risk models—in particular, the emerging concept of a risk/benefit tradeoff—all of which may ultimately allow the individual patient and the Heart Team to best determine the most appropriate revascularization strategy.

Table 1.

Summary of a selection of established and contemporary risk models categorized by anatomical, clinical, or combined types for the assessment of risk in patients proposing to undergo revascularization

Clinical risk score	Number of variables used to calculate risk		Outcomes
	Clinical	Angiographic
Anatomical- and functional-based scores
ACC/AHA lesion classification	0	11 (per lesion)	Pre drug-eluting stent era: predictive of angiographic success of PCI and prognostic effect on early and late clinical outcomes. Conflicting results in the drug-eluting stent era [10–13]
Myocardial Jeopardy scores			Encompasses severity of coronary artery lesions and the volume of myocardium subtended by the stenosis (ie, amount of myocardium at risk)
-Duke Jeopardy score	0	6a
-Myocardial Jeopardy index (BARI)	0	9	All predictive of mortality at 1 year after PCI or CABG [51].
-APPROACH lesion score	0	10a	PCI: APPROACH lesion score most predictive
			CABG: Duke Jeopardy score most predictive
SYNTAX score (SXscore)	0	11 (per lesion)	Quantifies coronary artery disease complexity by tertiles of SXscore: more events (death, MACCE) in the higher tertiles of risk at up to 3 years follow-up [2•, 7]
Functional SYNTAX score	0	11 (per lesion)	FFR-guided SXscore calculation improved prognostic ability of the SXscore: death/MI, MACE at 1 year [21]
Clinical-based scores
Parsonnet score	14	0	Operative mortality after open heart surgery [36]
New Mayo Clinic risk score	7	0	Procedural death and MACE for PCI [24]
			In-hospital death with CABG or PCI [25]
EuroSCORE (additive or logistic)	17	0	Operative mortality for all forms of cardiothoracic surgery [5, 6]
			Evidence for predicting death or MACCE in high-risk tertiles for PCI [27–29•, 30–32]
NCDR CathPCI risk score	8	0	30-day mortality rates after PCI in all patient types [52•]
ACEF score (age, creatinine, ejection fraction)	3	0	Operative mortality in elective cardiac operations [33, 34•]
			Predictor of cardiac death and MI at 1 year after PCI; inferior to the SXscore at predicting overall MACE and the risk of repeat revascularization [35]
Northern New England score	8	0	In-hospital mortality after CABG [53]
New York CABG risk index	10	0	In-hospital mortality after CABG [54]
Combined (anatomical and clinical based) risk scores
Society of Thoracic Surgery score	40	2	Operative morbidity and mortality for all forms of cardiothoracic surgery [55–57]
The Texas Heart Institute risk score	8	Angiographic: 2	Predictors of in-hospital MACE after PCI or CABG [58]
		Procedural: 1b
New York PCI risk score	8	1	In-hospital death for PCI procedures [59]
Parsonnet + SYNTAX score	14	11	MACCE and death at a median follow-up of 973 days (PCI) and 1298 days (CABG) [38]
Clinical SYNTAX score	3	11 (per lesion)	MACCE and death after PCI at 5 years follow-up [41]
NERS	17	Angiographic: 33	6-month cardiac death and cumulative MACE after unprotected LMS PCI [44]
		Procedural: 4c
Global Risk	17	11 (per lesion)	Death and MACCE after unprotected LMS PCI [43, 46]

^a Number of segments of myocardium at risk

^bNumber of stents.

^cNeed of IABP, two-stent technique, IVUS guidance

ACC American college of cardiology, AHA American heart association, APPROACH Alberta provincial project for outcome assessment in coronary heart disease, BARI bypass angioplasty revascularization investigation, CABG coronary artery bypass grafting, EuroSCORE European system for cardiac operative risk evaluation, IABP intra-aortic balloon pump, IVUS intravascular ultrasound, LMS left main stem, MACE major adverse cardiac events, MACCE major adverse cardiac and cerebrovascular events, MI myocardial infarction, NCDR national cardiovascular data registry, NERS new risk classification score, PCI percutaneous coronary intervention, SYNTAX synergy between percutaneous coronary intervention with taxus and cardiac surgery

Anatomical- and Functional-Based Risk Scores

In 1981, our group developed a coronary scoring system that assessed the severity and extent of the underlying coronary artery disease [8]. This system was based on the severity of luminal diameter narrowing and weighted according to the usual flow to the left ventricle in each coronary vessel. Consequently the most weight was given to the LMS, followed by the left anterior descending, circumflex, and right coronary arteries. This early pioneering work ultimately formed the basis of the SYNTAX score (SXscore) [7, 9]. Since then, numerous angiographic-based risk scores have been developed (Table 1), several of which are described below.

American College of Cardiology/American Heart Association Lesion Classification System

The American College of Cardiology/American Heart Association (ACC/AHA) lesion classification system was one of the first angiographic scoring systems developed, comprising of 11 angiographic variables with all lesions categorized into types (A, B1, B2, and C) [10]. This system was predictive of the angiographic success of PCI with a subsequent prognostic effect on the early and late clinical outcomes in the pre drug-eluting stent era. However, registry data from the drug-eluting stent era have had conflicting results. The German Cypher registry (n = 6755) failed to show any significant association with clinical outcomes at 6 months [11]; conversely, data from the ARTS II registry suggested an association with clinical outcomes for two and three-vessel disease (3VD) [12]. Furthermore, a small registry (n = 255) demonstrated this classification system to be potentially predictive of mortality in unprotected LMS PCI at 1-year follow-up [13].

SYNTAX Score

The SXscore is a well-described anatomical risk-based score that takes into account features such as bifurcations, total occlusions, thrombus, calcification, small vessels, and so forth. Each coronary lesion with a greater than 50% luminal obstruction lumen in vessels ≥ 1.5 mm are separately scored and summated to provide the overall SXscore. This is calculated using dedicated software that integrates the number of lesions with their specific weighting factors, based on the amount of myocardium distal to the lesion and morphologic features of each single lesion [7, 8, 9, 14].

Within the SYNTAX trial, [1] the distribution of the SXscore was found to be Gaussian in the randomized PCI and coronary artery bypass grafting (CABG) populations with the curves almost being superimposable (Fig. 1). When the scores of the randomized SYNTAX population were divided into tertiles, the upper boundary of the lowest tertile was 22 (low risk), the second tertile ranged from 23 to 32 (intermediate risk), and the lower boundary for the highest tertile is ≥ 33 (high risk).

Fig. 1.

The distribution of the SYNTAX score in the randomized and registry PCI and CABG populations from the SYNTAX trial. Note how the distributions for both the PCI and CABG registries are shifted to the right, whereas for the randomized population both curves are almost superimposable on each other [1, 7]. CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, RCT randomized controlled trial, SYNTAX Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery. (Reprinted from EuroIntervention; Serruys PW, Onuma Y, Garg S, et al.: Assessment of the SYNTAX score in the Syntax study. Copyright 2009, with permission from Europa Edition); [7]

The SXscore has since been consistently shown to demonstrate poorer outcomes and to be an independent predictor of major adverse cardiac events (MACE) in the high tertile group of risk for PCI with both multivessel and LMS disease at up to 5 years of follow-up [15]. This is maintained even with next-generation drug-eluting stents. For example, Wykrzykowska et al. [16] demonstrated in the LEADERS all-comers trial a higher rate of myocardial infarction (MI), target vessel revascularization, and MACE in highest tertile of the SXscore Of note is that within this study approximately 30% of the high SXscore risk tertile had 3VD compared with only 10% in the low SXscore risk tertile.

Within the CABG population, the SXscore however appears to have little predictive value for outcome. This is likely due to the simple fact that the bypass is anastomosed distal to the severe coronary disease, regardless of the complexity, provided there are suitable graftable targets [17].

Functional SYNTAX Score

The FAME study first established that by utilizing fractional flow reserve (FFR) measurements to determine the functional significance of individual coronary lesions and guide subsequent coronary intervention, that this leads to a potential prognostic impact when compared with angiographic guidance alone [18–20]. Consequently, by incorporating FFR measurements into the SXscore to form the recently dubbed, Functional SYNTAX score, it was shown in a retrospective subanalysis of almost 500 patients with multivessel disease from the FFR-guided arm of FAME, that this improved the risk stratification of patients when compared with the conventional angiographic-based SXscore [21]. The primary benefit appeared in reclassifying a significant proportion of the higher-risk groups into lower-risk categories while still maintaining a significantly higher event rate (death/MI and MACE at 1 year) in the high-risk groups. However, the study did not include LMS disease, and from a practical perspective, even if validated in larger prospective populations, is limited by the more invasive nature of the procedure.

One of the criticisms of the FAME study was that quantitative coronary angiography (QCA) was not used to assess vessel size and instead was reliant on visual estimation [22]. Visual assessment is well known to be associated with poor reproducibility and often overestimates lesion significance [10]. If QCA had been used to assess vessel size, then the potential benefit seen in favor of FFR may have been less. The practice of visual assessment of vessel/lesion size is however representative of real-life practice and was also the basis of how the SXscores were calculated within the SYNTAX study. Novel techniques to potentially simplify the generation of the newly developed Functional SYNTAX score include the use of noninvasive computed tomographic angiography that allows for the simultaneous assessment of anatomy and the measurement of the hemodynamic significance of lesions (Heartflow, Redwood City, California, USA) .

Limitations

The progressive development of anatomical-based risk scores culminating in the Functional SYNTAX score has undoubtedly improved the performance of these risk models in terms of stratification for the individual patient. However, the limiting factors are the inevitable variability in coronary angiogram assessment if visual assessment is used to assess the vessel/lesion size [7, 23]. With the potential use of the Functional SYNTAX score this problem may be circumvented, especially if a noninvasive assessment of the Functional SYNTAX score is developed as mentioned. The other limiting factors are that no clinical variables are used, which in themselves are less subjective than some angiographic variables; consequently, important prognostic information may potentially be missing that may aid in risk stratifying these patients further.

Clinical-Based Risk Scores

The main advantages of clinical-based scores are that they are potentially easier to perform and less subjective compared with purely anatomical-based scores that require interpretation of the coronary angiogram. They can also be performed relatively quickly and often at bedside if necessary.

EuroSCORE

The EuroSCORE is an established risk model, which utilizes 17 clinical variables within cardiothoracic practice for predicting operative mortality [5, 6, 26]. In use since 1999, the model was derived from almost 20,000 consecutive patients from 128 hospitals in eight European countries. The additive model assigns an individual score to 17 clinical variables and has been validated in many populations around the world. These studies have consistently demonstrated that among cardiothoracic surgery patients, a low EuroSCORE risk tertile ranges from 1 to 2, intermediate-risk tertile from 3 to 5, and a high-risk tertile of 6+ (Table 2). The subsequently developed logistic EuroSCORE allows for a more accurate risk prediction within the CABG cohort, in particular for the high-risk patient in which the additive model was found to lead to a potential underestimation of risk.

Table 2.

The concept of the Global Risk approach, combining the additive EuroSCORE and SYNTAX score (SXscore) using historically defined tertiles of risk for the EuroSCORE [5, 26] and the SYNTAX trial–defined ranges for SXscore [1, 7]

	Low SXscore (≤ 22)	Intermediate SXscore (23–32)	High SXscore (≥ 33)
Low additive EuroSCORE (0–2)	Low risk	Low risk	Intermediate risk
Intermediate additive EuroSCORE (3–5)	Low risk	Low risk	Intermediate risk
High additive EuroSCORE (≥ 6)	Intermediate risk	Intermediate risk	High risk

EuroSCORE European system for cardiac operative risk evaluation, SYNTAX synergy between percutaneous coronary intervention with taxus and cardiac surgery

Kim et al. [27] first demonstrated that the high-risk tertile of the EuroSCORE was an independent predictor of death/MI after unprotected LMS intervention with sirolimus-eluting stents. Subsequently, Romagnoli et al. [28] applied the additive EuroSCORE to predict in-hospital mortality in 1173 consecutive patients undergoing PCI in a single high-volume center and correlated the higher-risk tertiles of the EuroSCORE with in-hospital mortality. This included patients who had undergone unprotected LMS PCI [28]. In addition, several studies have since all identified the additive EuroSCORE as an independent predictor of major adverse cardiac and cerebrovascular events (MACCE) among patients with unprotected LMS PCI at up to 4 years of follow-up [27, 29•, 30–32]. Only one study has examined the logistic EuroSCORE in PCI patients; however, little differences were found in stratifying risk when compared with the additive EuroSCORE [28].

ACEF Score

Ranucci et al. [33, 34•] demonstrated in a relatively simple risk model consisting of only three clinical variables—age, preoperative serum creatinine value, and left ventricular ejection fraction—a risk model for assessing operative mortality risk in elective cardiac operations. Of note is that despite the simplicity of the model, its clinical performance appeared to be equivalent to either the additive or the logistic EuroSCOREs [33, 34•].

The ACEF score is calculated using the formula:

From this score, a mortality risk can be calculated from a graphical relationship of the score with an operative risk or an equation [33, 34•].

The ACEF model was recently applied to PCI patients from the all-comers LEADERS population at 1-year follow-up [35]. Despite the ACEF score being demonstrated to be superior to the SXscore alone as a predictor of cardiac death and MI after PCI, the ACEF score was found to be inferior to the SXscore at predicting overall MACE and the risk of repeat revascularization. This reflects the observation that anatomical and clinical variables appear to be a necessary requirement for a comprehensive risk model in predicting clinical outcomes with PCI.

Limitations

The main limitations of the clinical-based risk scores alone are predominantly related to the lack of anatomical variables which in themselves may carry additional prognostic information, such as the SYNTAX score as previously discussed.

Combined (Anatomical and Clinical) Based Risk Scores

SYNTAX Score and the Parsonnet Score

By combining the Parsonnet score, an operative risk score published in 1989 consisting of 14 clinical variables [36], with the SXscore, it has been shown that this may potentially improve the performance of the SXscore alone. In 2005, Valgimigli et al. [37] demonstated that the Parsonnet score was an independent predictor of MACE after LMS intervention from the Rotterdam RESEARCH and T-SEARCH registries. More recently, Chakravarty et al. [38] demonstrated that by adding the Parsonnet score as a covariate to the SXscore, this improved the ability of the score in predicting MACCE after LMS PCI.

Clinical SYNTAX Score

The underlying rationale for the Clinical SYNTAX Score was to combine, by multiplication, the SXscore and a variant of the ACEF score (modified ACEF score), of which the latter had proven to be comparable to the EuroSCORE in elective CABG patients as previously described [33, 34•]. The modified ACEF score was used instead of ACEF score in this model as it had previously been demonstrated that this potentially allowed for a more accurate assessment of the underlying renal function and had subsequently improved the accuracy of cardiac prediction models such as the EuroSCORE [39–41]. The modified ACEF score is calculated by using the formula: age/ejection fraction + 1 point for every 10-ml/min reduction in creatinine clearance below 60 ml/min/1.73 m² (up to a maximum of 6 points).

This model was applied to the ARTS II population treated with sirolimus-eluting stents for multivessel coronary artery disease by our group [41, 42]. By dividing the calculated Clinical SYNTAX scores into tertiles of risk, it was demonstrated that the risk model for predicting outcomes for MACCE and death at 5 years was superior to the SXscore or modified ACEF scores alone. One of the limiting factors of the Clinical SYNTAX score was that despite being able to predict events accurately in the high-risk tertile, the risk model was unable to discriminate between the end points for the low- and intermediate-risk tertiles [41]. This was also recently demonstrated within a registry of patients undergoing left main PCI [43].

New Risk Classification Score

The New Risk Classification Score (NERS) [44] is a risk model developed to predict outcomes for unprotected LMS PCI from four centers in China (n = 260). Reflecting the long period over which this registry was performed (~ 10 years), the patients included had either bare-metal or drug-eluting stent implantation. The model was subsequently validated in a different consecutive group of patients within the same registry all treated with drug-eluting stents (n = 337).

This risk model consists of 54 variables (17 clinical, 4 procedural, and 33 angiographic features). A substantially higher c-statistic was evident for the NERS compared with the SXscore (NERS: 0.89 vs SXscore: 0.69), indicating that it had an excellent discriminatory ability. When the NERS score was separated into two groups of risk (high and low) and clinical outcomes assessed, the high-risk group was demonstrated to be significantly more predictive of MACE compared with the intermediate or high SXscore tertiles.

In the low-risk NERS group, outcomes were similar to the low SXscore group, suggesting at least from this study that anatomical variables alone may be sufficient to be predict outcomes in the low-risk group. However, patient comorbidity was significantly less prevalent in the NERS patient population compared with the all-comers SYNTAX population [1, 3], the latter of which was designed to overcome many of the limitations/bias selections inherent in small registries. Validation of the NERS risk model in a much larger, randomized population of patients is therefore required.

Global Risk

The SYNTAX trial established a complex interaction between the EuroSCORE and the SXscore. The need to combine the angiographic and clinical scores into a single approach consequently became evident [45].

The Global Risk approach (Table 2) aims to potentially combine established historically accepted clinical variables from the EuroSCORE [5, 6] with anatomical variables from the SXscore [7, 9, 14] to allow for a Global Risk assessment for patients proposing to undergo revascularization with PCI [45]. By adopting this approach, the same risk model could potentially be used by the Heart Team to appropriately risk stratify patients proposing to undergo PCI or CABG. This may potentially increase the number of patients who could safely and efficaciously be treated with PCI compared to the use of the SYNTAX score alone.

In variants of this model, one group has previously demonstrated the potential of the Global Risk model to enhance risk stratification among patients who underwent LMS PCI from a single-center registry [43, 46]. A major criticism of their approach has been the lack of consistency in their application of the Global Risk model. The range of scores within each tertile of risk for the EuroSCORE and SXscores has been established as described earlier [5–7, 9, 14]. Yet in the two publications using the Global Risk approach by the same group [43, 46], a different range of scores for the tertiles of risk for the EuroSCORE and SXscores has been used [46, 47]. It is the authors’ opinions that the established range of scores for the tertiles of risk for the EuroSCORE and SXscore (Fig. 1) should be maintained to allow the application of the Global Risk model across surgical and PCI populations, and importantly allow for a consistency in the ranges of scores that will make application of the model by other groups possible and ultimately may allow validation of this risk model in the future, should this risk model prove feasible. Further study into the concept of a Global Risk approach utilizing the EuroSCORE and SXscores with ranges of risks based on consistently defined values for the EuroSCORE and SXscore tertiles are forthcoming.

Risk/Benefit Analysis

Undoubtedly, both PCI and CABG allow for an improvement in the quality of life for patients. However, one of the main drawbacks of using contemporary risk models for both PCI and CABG is that the role of the individual patient, their personal preferences, and perception of risk may be underestimated. To address this issue, the novel concept of a clinical model that balances the risks and benefits of the proposed revascularization procedure has recently emerged [48•].

Essentially the need for some individuals to remain active within their professional/personal lives may be vital, and they would thus potentially be more prepared to accept the longer-term risks associated with PCI—namely increased revascularization—to remain at their present functional state, in exchange for being free from the short-term morbidity associated with CABG. The latter being predominantly related to the intrinsically more invasive nature of the CABG procedure (eg, thoracotomy and vein harvesting and subsequent sternotomy and leg pain) [49, 50]. However, individual patients may value this risk/benefit tradeoff differently. For some, exchanging the increased risk of repeat PCI or CABG to obtain short-term pain relief and a rapid return to full mobility will be acceptable, whereas others may prefer to endure short-term pain to obtain a higher probability of avoiding a subsequent revascularization. Patients may also prefer to risk undergoing multiple PCI procedures rather than a single CABG, or they may prefer to avoid the risk of requiring CABG subsequent to PCI and instead have CABG initially. Consequently, from the patient’s perspective, the balance between these conflicting considerations appears to play a crucial role in the identification of the preferred revascularization strategy.

Federspiel et al. [48•] recently applied this concept to the ARTS I population, by quantifying the tradeoff between the risks and benefits of PCI versus CABG for patients with multivessel disease [42]. Although this study was performed on study data that were over 10 years old, in a population who had implantation of bare-metal stents, the results were nevertheless supportive of this concept and allowed for the first time a quantification of a level of risk that a patient would be willing to accept to maintain their present functional state. Data from the SYNTAX and other trials on this very concept to reflect more contemporary practice with drug-eluting stents are forthcoming.

Conclusions

It would appear that a combination of clinical and anatomical variables are required for an effective, clinically useful risk model for patients with complex coronary artery disease proposing to undergo multivessel PCI. Ideally this model would be simple to calculate and could be rapidly performed at the bedside. However, the need to include detailed anatomical assessments appears evident, such as the incorporation of the SXscore. The pragmatic approach appears in developing and refining a risk model that incorporates both elements in as simple a way as possible. Concepts such as the noninvasive calculation of the Functional SYNTAX score may serve to streamline this process and the concept of patient-empowered risk/benefit tradeoff are potential further areas for research.

Clinical Trial Acronyms

ARTS

Arterial Revascularization Therapies Study

FAME

Fractional Flow Reserve Versus Angiography for Guiding PCI in Patients with Multivessel Evaluation

LEADERS

Limus Eluted from a Durable Versus Erodable Stent Coating

RESEARCH

Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital

SYNTAX

Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery

T-SEARCH

Taxus Stent Evaluated at Rotterdam Cardiology Hospital.